Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC

RAISE is an international, multicentre, single-arm phase II trial. The trial treatment consists of the addition of niraparib, 200 mg orally once daily to anti-PD-L1 antibody maintenance. The primary objective of this trial is to assess the clinical efficacy of the addition of niraparib to anti-PD-L1 monoclonal antibody maintenance treatment in patients with SLFN11-positive ED-SCLC which has not progressed following standard first-line chemo-immunotherapy.

Trial Details

NCT ID
NCT05718323
Phase
PHASE2
Sponsor
ETOP IBCSG Partners Foundation
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Niraparib
Locations (sample)
  • Angers, France|47.47156,-0.55202
  • Avignon, France|43.94834,4.80892
  • Caen, France|49.18585,-0.35912
  • Lyon, France|45.74906,4.84789
  • München, Germany|51.60698,13.31243

Key Eligibility Criteria

  • Inclusion criteria for SLFN11-expression testing
  • Written IC part 1: for SLFN11-screening must be signed and dated by the patient and the investigator prior to sending any tumour material to the ce…
  • Histologically or cytologically confirmed ED-SCLC (stage IV according to the 8th TNM classification).
  • Availability of FFPE tumour tissue for screening.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →